ARK Investment buys 560K shares of Intellia Therapeutics

* Cathie Wood's ARK Investment has purchased 560,600 shares of biotech and gene editing company Intellia Therapeutics (NASDAQ:NTLA [https://seekingalpha.com/symbol/NTLA]).
* The stock has a Seeking Alpha quant rating of Hold, [https://seekingalpha.com/symbol/NTLA/ratings/quant-ratings]with the factor grades given to momentum.
* SA Investing Group Leader Edmund Ingham recently upgraded his rating to Buy [https://seekingalpha.com/article/4814086-intellia-therapeutics-it-may-be-time-to-get-excited-and-buy-upgrade], citing its lead gene-editing therapies, Lonvo-z and Nex-z, potential with 'one and done' treatment and strong early efficacy and safety data. ''Despite risks, I see NTLA stock as a compelling long-term Buy with triple-digit percentage upside if efficacy and safety are confirmed in late-stage trials." he wrote.
* The stock price traded ~1% higher to $10.83 on Monday during after-market hours of trading.

MORE ON INTELLIA THERAPEUTICS

* Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade) [https://seekingalpha.com/article/4814086-intellia-therapeutics-it-may-be-time-to-get-excited-and-buy-upgrade]
* Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4810697-intellia-therapeutics-inc-ntla-q2-2025-earnings-call-transcript]
* With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy' [https://seekingalpha.com/article/4802131-with-intellia-therapeutics-human-patience-beat-hot-take-trading-still-at-buy]
* Intellia targets 1,200 patients in expanded Phase III ATTR cardiomyopathy trial as enrollment accelerates [https://seekingalpha.com/news/4482160-intellia-targets-1200-patients-in-expanded-phase-iii-attr-cardiomyopathy-trial-as-enrollment]
* Intellia Therapeutics Q2 2025 Earnings Preview [https://seekingalpha.com/news/4480099-intellia-therapeutics-q2-2025-earnings-preview]